Literature DB >> 7380543

Antitoxic immunity to cholera in dogs immunized orally with cholera toxin.

N F Pierce, W C Cray, P F Engel.   

Abstract

Colera toxin was evaluated as an oral immunogen against experimental canine cholera. Dogs were immunized orally with 100-microgram doses of purified cholera toxin or comparable doses of crude toxin. Both doses caused moderate diarrhea in most nonimmune dogs. Repeated oral doses (12 doses in 54 days) gave marked protection against the diarrheal effect of oral toxin, provoked a vigorous antitoxic response in jejunal mucosa, and gave nearly complete protection against subsequent oral challenge with living virulent Vibrio cholerae. Protection appeared to be due largely to the antitoxic response in intestinal mucosa. The effectiveness of cholera toxin as an oral vaccine contrasts with the previously described ineffectiveness of toxoid given orally. This study provides an example of mucosal immunity due to a nonreplicating vaccine given orally and suggests that cholera toxin may be useful as a component of an oral vaccine for cholera.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7380543      PMCID: PMC550811          DOI: 10.1128/iai.27.2.632-637.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Immunity to experimental cholera. II. Secretory and humoral antitoxin response to local and systemic toxoid administration.

Authors:  N F Pierce; H Y Reynolds
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

2.  Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine.

Authors:  R A Cash; S I Music; J P Libonati; J P Craig; N F Pierce; R B Hornick
Journal:  J Infect Dis       Date:  1974-10       Impact factor: 5.226

3.  Vibrio cholerae choleragenoid. Mechanism of inhibition of cholera toxin action.

Authors:  P Cuatrecasas
Journal:  Biochemistry       Date:  1973-08-28       Impact factor: 3.162

4.  Protection against experimental cholera by antitoxin.

Authors:  N F Pierce; E A Kaniecki; R S Northrup
Journal:  J Infect Dis       Date:  1972-12       Impact factor: 5.226

5.  Antitoxic immunity in experimental cholera: comparison of immunity induced perorally and parenterally in mice.

Authors:  K Fujita; R A Finkelstein
Journal:  J Infect Dis       Date:  1972-06       Impact factor: 5.226

6.  Experimental canine cholera. I. Development of the model.

Authors:  R B Sack; C C Carpenter
Journal:  J Infect Dis       Date:  1969-02       Impact factor: 5.226

7.  Systemic effects of parenteral cholera enterotoxin in dogs.

Authors:  N F Pierce; J R Graybill; M M Kaplan; D L Bouwman
Journal:  J Lab Clin Med       Date:  1972-01

8.  Test for enterotoxigenic Escherichia coli using Y-1 adrenal cells in miniculture.

Authors:  D A Sack; R B Sack
Journal:  Infect Immun       Date:  1975-02       Impact factor: 3.441

9.  Vibriocidal and agglutinating antibody patterns in cholera patients.

Authors:  R B Sack; D Barua; R Saxena; C C Carpenter
Journal:  J Infect Dis       Date:  1966-12       Impact factor: 5.226

10.  Pathogenesis of experimental cholera. Preparation and isolation of choleragen and choleragenoid.

Authors:  R A Finkelstein; J J LoSpalluto
Journal:  J Exp Med       Date:  1969-07-01       Impact factor: 14.307

View more
  15 in total

1.  Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes.

Authors:  A M Svennerholm; L Gothefors; D A Sack; P K Bardhan; J Holmgren
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

2.  Enhanced mucosal priming by cholera toxin and procholeragenoid with a lipoidal amine adjuvant (avridine) delivered in liposomes.

Authors:  N F Pierce; J B Sacci
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

3.  Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo.

Authors:  F M Apter; P Michetti; L S Winner; J A Mack; J J Mekalanos; M R Neutra
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

4.  Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms.

Authors:  N F Pierce; W C Cray; J B Sacci
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

5.  Effect of chemical and heat inactivation on the antigenicity and immunogenicity of Vibrio cholerae.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

6.  Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera.

Authors:  N F Pierce; W C Cray; J B Sacci; J P Craig; R Germanier; E Fürer
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

7.  Protection of rat intestine against cholera toxin challenge by monoclonal anti-idiotypic antibody immunization via enteral and parenteral routes.

Authors:  G P Lucas; C L Cambiaso; J P Vaerman
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

8.  Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.

Authors:  Gregory M Glenn; Christina P Villar; David C Flyer; A Louis Bourgeois; Robin McKenzie; Robert M Lavker; Sarah A Frech
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

9.  Arousal of mucosal secretory immunoglobulin A antitoxin in rats immunized with Escherichia coli heat-labile enterotoxin.

Authors:  F A Klipstein; R F Engert; J D Clements
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

10.  Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli.

Authors:  Jianmei Yu; Frederick Cassels; Tanya Scharton-Kersten; Scott A Hammond; Antoinette Hartman; Evelina Angov; Blaise Corthésy; Carl Alving; Gregory Glenn
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.